A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

被引：13

作者：

Patel, Manish R. ^{[1
]}

Monga, Varun ^{[2
]}

Jauhari, Shekeab ^{[1
]}

Stevens, Don ^{[3
]}

Masarova, Lucia ^{[4
]}

McKean, Meredith ^{[5
]}

Mauro, David ^{[6
]}

Viscusi, John ^{[6
]}

Scherle, Peggy ^{[6
]}

Bhagwat, Neha ^{[6
]}

Moore, Andrew ^{[6
]}

Sun, William ^{[6
]}

Chiaverelli, Rachel ^{[6
]}

Mintah, Eric ^{[6
]}

Nath, Rajneesh ^{[7
]}

Stein, Eytan M. ^{[8
]}

Palmisiano, Neil ^{[9
]}

Sutamtewagul, Grerk ^{[2
]}

Verstovsek, Srdan ^{[10
]}

机构：

[1] Florida Canc Specialists & Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA

[2] Univ Iowa Hosp & Clin, Dept Med, Iowa City, IA 52242 USA

[3] NCI, Norton Healthcare, Louisville, KY USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[6] Prelude Therapeut, Res & Dev, Wilmington, DE USA

[7] Univ Texas MD Anderson Canc Ctr, Banner Hlth, Gilbert, AZ USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[9] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-150938

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2609

引用

页数：7

共 50 条

[1] A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with advanced solid tumors and lymphoma
McKean, Meredith
Patel, Manish R.
Wesolowski, Robert
Ferrarotto, Renata
Stein, Eytan M.
Shoushtari, Alexander N.
Mauro, David
Viscusi, John
Scherle, Peggy
Bhagwat, Neha
Sun, William
Chiaverelli, Rachel
Mintah, Eric
Jauhari, Shekeab
Finn, Laura
Palmisiano, Neil D.
Baiocchi, Robert A.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[2] Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
Bewersdorf, Jan Philipp
Mi, Xiaoli
Lu, Bin
Kuykendall, Andrew
Sallman, David
Patel, Manish
Stevens, Don
Philipovskiy, Alexander
Sutamtewagul, Grerk
Masarova, Lucia
Keiffer, Gina
Verma, Amit
Bhagwat, Neha
Wang, Min
Moore, Andrew
Rager, Joseph
Heiser, Diane
Ro, Sunhee
Hong, Wan-Jen
Abdel-Wahab, Omar
Stein, Eytan M.
LEUKEMIA, 2025, 39 (03) : 765 - 769
[3] Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
Bewersdorf, Jan Philipp
Mi, Xiaoli
Lu, Bin
Kuykendall, Andrew T.
Sallman, David
Patel, Manish
Stevens, Don A.
Philipovskiy, Alexander
Sutamtewagul, Grerk
Masarova, Lucia
Keiffer, Gina
Uerma, Amit
Bhagwat, Neha
Heiser, Diane
Ro, Sunhee
Hong, Wan-Jen
Abdel-Wahab, Omar
Stein, Eytan M.
BLOOD, 2024, 144 : 3217 - 3217
[4] Preclinical characterization of PRT543, a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), with broad antitumor activity in in vitro and in vivo models
Bhagwat, Neha
Zhang, Yang
Lin, Hong
Wang, Min
Rominger, Dave
Emm, Tom
Chugani-Mahtani, Divya
Angelis, Dimitrios
Shetty, Rupa
Leal, Raul
Gowen-MacDonald, William
Grego, Alexander
Luengo, Juan
Manshouri, Taghi
Pastore, Friederike
Levine, Ross L.
Verstovsek, Srdan
Ruggeri, Bruce
Scherle, Peggy
Vaddi, Kris
CANCER RESEARCH, 2020, 80 (16)
[5] Preclinical Activity of the Clinical Stage Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Splicing Mutant Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Schwartz, Leya Y.
Choudhary, Gaurav S.
Ramachandra, Nandini
Sahu, Srabani
Gordon, Shanisha
Ruggeri, Bruce
Heiser, Diane
Scherle, Peggy
Starczynowski, Daniel
Verma, Amit
BLOOD, 2021, 138
[6] PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study
Ferrarotto, Renata
Swiecicki, Paul L.
Zandberg, Dan P.
Baiocchi, Robert A.
Wesolowski, Robert
Rodriguez, Cristina P.
Mckean, Meredith
Kang, Hyunseok
Monga, Varun
Nath, Rajneesh
Palmisiano, Neil
Babbar, Naveen
Sun, William
Hanna, Glenn J.
ORAL ONCOLOGY, 2024, 149
[7] A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) brain penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade gliomas
Falchook, Gerald S.
Glass, Jon
Monga, Varun
Giglio, Pierre
Mauro, David
Viscusi, John
Scherle, Peggy
Bhagwat, Neha
Sun, William
Chiaverelli, Rachel
Mintah, Eric
Clements, Lydia
Johanns, Tanner M.
McKean, Meredith
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[8] Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors
Lin, Hong
Luengo, Juan, I
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (11) : 1264 - 1269
[9] Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)
Palte, Rachel L.
Schneider, Sebastian E.
Altman, Michael D.
Hayes, Robert P.
Kawamura, Shuhei
Lacey, Brian M.
Mansueto, My Sam
Reutershan, Michael
Siliphaivanh, Phieng
Sondey, Christopher
Xu, Haiyan
Xu, Zangwei
Ye, Yingchun
Machacek, Michelle R.
ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (09): : 1688 - 1693
[10] Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery
Wang, Yuanxiang
Hu, Wenhao
Yuan, Yanqiu
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (21) : 9429 - 9441

← 1 2 3 4 5 →